Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models
Preprint
Abstract
Background: Malignant gliomas (MG) are the most common primary brain malignancies and are considered universally fatal. Oncolytic HSVs (oHSV) are promising immunotherapeutics capable of selectively lysing cancer cells, eliciting anti-tumor immunity, and providing local delivery of immune-activating transgenes. IL-27 is a pleiotropic cytokine capable of enhancing tumor-reactive cytotoxic T cell (CTL) function while also possessing neuroprotective properties. We hypothesized that IL-27 expression by oHSV would enhance CTL function and improve anti-glioma therapeutic activity. Methods: We developed an oncolytic herpes simplex virus (oHSV) that expresses IL-27 (C027). The anti-glioma efficacy of C027 was tested in three syngeneic orthotopic glioma models derived from both chemical (CT-2A) and genetic (SB28, KR158) glioma lines. Spectral flow cytometry was used to assess immunophenotypic and functional changes in the tumor infiltrates and systemically. To further investigate the C027-related CTL activity, we employed in vivo cell specific depletion and IL-27 blockade alongside in vitro T cell stimulation assays. Local and systemic antitumor memory was evaluated by both orthotopic and flank tumor rechallenge of C027-treated long-term survivors. Results: C027 significantly prolonged survival in syngeneic orthotopic glioma models derived from both chemical (CT-2A) and genetic (KR158, SB28) glioma lines. In the CT-2A model, IL-27-expressing oHSV treatment was associated with increased intratumoral multifunctional effector cytotoxic T lymphocytes (CTL) and functional T cell populations systemically. Mechanistically, both CD8 T cells and IL-27 were required for the C027 survival benefit in vivo and IL-27 enhanced CTL function in vitro . C027-treated mice that survived their initial tumors had local and systemic anti-glioma memory rejecting tumors on rechallenge. Conclusions: Our findings demonstrate that IL-27 expression by oHSV significantly improves anti-glioma therapeutic efficacy, enhances CTL effector function, and induces durable immune memory. Thus, IL-27-oHSV may provide a promising therapeutic approach for malignant gliomas. What is already known on this topic – Malignant gliomas are highly aggressive tumors largely resistant to current immunotherapies. Oncolytic herpes simplex viruses (oHSV) are promising immunotherapy agents for malignant gliomas and provide a platform for immunomodulatory gene expression. What this study adds – In this study, we present a novel IL-27 expressing oHSV (C027) that improves survival in syngeneic glioma-bearing mice through a CD8 T cell and IL-27 dependent mechanism and induces durable immune memory. How this study might affect research, practice or policy – Our study demonstrates that IL-27-expression by oHSV enhances anti-tumor immunity and glioma efficacy suggesting its potential as a novel therapeutic.Keywords
All Related Versions
- Published version: Journal for ImmunoTherapy of Cancer, 13 (7), e012227.
Funding Information
- National Institutes of Health (U54-CA232561)
- National Institutes of Health (U54-CA232561S)
- National Institutes of Health (T32-CA269052)
- U.S. Department of War (HT9425-23-1-0803)
This publication has 50 references indexed in Scilit:
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Advances in understanding the anti-inflammatory properties of IL-27Immunology Letters, 2008
- T-cell quality in memory and protection: implications for vaccine designNature Reviews Immunology, 2008
- Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic virusesGene Therapy, 2007
- Human Cytomegalovirus TRS1 and IRS1 Gene Products Block the Double-Stranded-RNA-Activated Host Protein Shutoff Response Induced by Herpes Simplex Virus Type 1 InfectionJournal of Virology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- IL-27, a Heterodimeric Cytokine Composed of EBI3 and p28 Protein, Induces Proliferation of Naive CD4+ T CellsImmunity, 2002
- Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effectsNature Genetics, 2000
- The influence of ImuVert, a biological response modifier, on the growth and ganglioside composition of murine neural tumorsMolecular and Chemical Neuropathology, 1993
- A generalized technique for deletion of specific genes in large genomes: a gene 22 of herpes simplex virus 1 is not essential for growthCell, 1981